IGF-1 LR3 Research Peptide

In short: IGF-1 LR3 (Long R3 IGF-1) is a synthetic, modified analogue of insulin-like growth factor 1, supplied strictly for in-vitro laboratory research and not approved for human consumption. It is used as a reference compound in cell-signalling and growth-factor studies. When sourcing it for research, buyers should insist on ≥99% purity by HPLC, identity confirmation by mass spectrometry, and clear batch numbering so results are traceable.

What is IGF-1 LR3?

IGF-1 LR3 is an engineered variant of human IGF-1, an 83-amino-acid peptide compared with the 70-amino-acid native molecule. It carries an N-terminal extension of 13 residues and a substitution of glutamic acid with arginine at position 3 — the “R3” in its name. Together these modifications sharply reduce its affinity for IGF-binding proteins (IGFBPs), which in laboratory systems extends its apparent stability relative to unmodified IGF-1. It was originally developed as a research tool for studying IGF-receptor signalling without the confounding influence of binding-protein interactions.

What does the research investigate?

Pre-clinical work with IGF-1 LR3 is largely confined to cell culture and animal models. In vitro studies using myoblasts, fibroblasts, adipocytes and neuronal cells have examined how the analogue interacts with the IGF-1 receptor to influence proliferation, differentiation, protein-synthesis signalling, glucose uptake and cell-survival pathways. Reports describe activity at lower concentrations than native IGF-1, attributed to reduced IGFBP sequestration. Controlled human data are very limited, and these pre-clinical observations do not establish human safety or efficacy. Always read the primary sources directly.

Purity and quality: what research buyers should check

≥99% purity by HPLC (confirm via the batch certificate of analysis, or COA)
Identity confirmed by mass spectrometry
Batch numbering for full traceability

Vexar Lab supplies IGF-1 LR3 as a pack of 10 vials, ≥99% HPLC-verified, batch-numbered, with mass-spec confirmation.

Handling and storage

Standard lyophilised-peptide practice applies. Store sealed vials at -20°C protected from light and moisture. After reconstitution with an appropriate sterile diluent, keep refrigerated at 2–8°C and use within the period indicated for your protocol. Avoid repeated freeze–thaw cycles, which can degrade peptide integrity. Allow vials to reach room temperature before opening to limit condensation.

Wholesale supply

Vexar Lab supplies research peptides in packs of 10 vials, with a £300 minimum order, bulk pricing on volume, £45 flat worldwide shipping, and optional custom labelling for resellers.

Frequently asked questions

Is IGF-1 LR3 approved for human use?

No. IGF-1 LR3 is not approved by any regulatory authority for human consumption, therapeutic, or veterinary use. It is supplied solely for in-vitro laboratory research.

How does IGF-1 LR3 differ from native IGF-1?

It has an N-terminal extension and an arginine substitution at position 3 that lower its binding-protein affinity, making it a useful tool for isolating receptor-level signalling in research models.

What purity should research-grade IGF-1 LR3 meet?

Look for ≥99% by HPLC with a batch COA and mass-spec identity confirmation to ensure traceable, reproducible results.

This guide is for laboratory research reference only. IGF-1 LR3 is supplied strictly for in-vitro research use and is not for human or animal consumption, nor for any diagnostic or therapeutic application.